Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.38 |
| ▸ | C5AR1 | P21730 | 9/20 | 0.37 |
| ▸ | ABL1 | P00519 | 3/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | PNMT | P11086 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30469196 | 1.00 | TRPV3 (0.38) | TRPV3C5AR1ABL1PDE10APNMT | |
| SCHEMBL31067853 | 1.00 | TRPV3 (0.38) | TRPV3C5AR1ABL1PDE10APNMT | |
| SCHEMBL30469181 | 1.00 | TRPV3 (0.38) | TRPV3C5AR1ABL1PDE10APNMT | |
| SCHEMBL25250725 | 1.00 | TRPV3 (0.38) | TRPV3C5AR1ABL1PDE10APNMT | |
| SCHEMBL25250727 | 1.00 | TRPV3 (0.38) | TRPV3C5AR1ABL1PDE10APNMT | |
| SCHEMBL25236451 | 0.84 | C5AR1 (0.41) | C5AR1OPRD1OPRL1OPRK1 | |
| SCHEMBL25236450 | 0.84 | C5AR1 (0.41) | C5AR1OPRD1OPRL1OPRK1 | |
| SCHEMBL25213573 | 0.84 | C5AR1 (0.41) | C5AR1OPRD1OPRL1OPRK1 | |
| SCHEMBL25240948 | 0.82 | C5AR1 (0.36) | C5AR1PDE10APNMTOPRD1OPRL1 | |
| SCHEMBL25240728 | 0.82 | C5AR1 (0.36) | C5AR1PDE10APNMTOPRD1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400579-A1 | SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | GENENTECH, INC. | 2024-12-05 | — | — | US | disclosed |
| WO-2023097234-A1 | SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | GENENTECH, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023097234-A1 | SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | GENENTECH, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400579-A1 | SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | MAG, NR1H2, PMP22 | TRPV3 3991/4885C5AR1 2709/4885ABL1 4690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.